The company has issued additional royalty-free, non-exclusive voluntary licences to Dr Reddy’s, MSN Laboratories and Torrent Pharmaceuticals, who will be collaborating with Lilly to accelerate and expand the availability of Baricitinib in India, Eli Lilly and Company said in a statement.
